Track topics on Twitter Track topics that are important to you
Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.
Important Product Safety Information
Aranesp® is contraindicated in patients with uncontrolled hypertension. Erythropoietic therapies may increase the risk of thrombotic events and other serious events. Seizures have occurred in patients with CRF. The target hemoglobin (Hb) should not exceed 12 g/dL. If the Hb increase exceeds 1.0 g/dL in any 2-week period, dose reductions are recommended. In a study of Epoetin alfa treated hemodialysis patients with clinically evident cardiac disease, where the target hematocrit (Hct) was 42% (Hb = 14 g/dL), an increased incidence of thrombotic events and mortality was seen. The reason for increased mortality observed in this study is unknown. In a study with another erythropoietic product, in women with metastatic breast cancer receiving chemotherapy, where the target Hb was 12-14 g/dL, an increased incidence of thrombotic events, disease progression, and mortality was seen
These highlights do not include all the information needed to use Aranesp safely and effectively. See full prescribing information for Aranesp. Aranesp(darbepoetin alfa)injection, for intravenous or s...
The purpose of this study was to evaluate Aranesp® administered subcutaneously (SC) to maintain hemoglobin (Hb) levels in renal transplant recipients.
The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).
The purpose of this trial is to assess the effectiveness of Aranesp® administered at 300 mcg every 3 weeks (q3w) in achieving therapeutic objectives of anemia treatment (achieving and mai...
The purpose of this trial is to prospectively assess the relationship between changes in hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients receiving ...
The purpose of this study is to assess the Aranesp® dose administered intravenously (IV) once weekly to maintain hemoglobin (Hgb) levels in hemodialysis subjects who are either recombinan...
Aranesp® (darbepoetin alfa) is approved for the treatment of anemia associated with chronic kidney disease and chemotherapy.
Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of...
We have published hundreds of Aranesp news stories on BioPortfolio along with dozens of Aranesp Clinical Trials and PubMed Articles about Aranesp for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aranesp Companies in our database. You can also find out about relevant Aranesp Drugs and Medications on this site too.
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells. In vertebrates, it is composed of blo...
Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...